Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612

PHASE3CompletedINTERVENTIONAL
Enrollment

697

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Infections, Meningococcal
Interventions
PROCEDURE

Blood Sampling

A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study

Trial Locations (5)

1781

GSK Investigational Site, City of Muntinlupa

110002

GSK Investigational Site, New Delhi

403202

GSK Investigational Site, Goa

452001

GSK Investigational Site, Indore

411 011

GSK Investigational Site, Pune

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00974363 - Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK 134612 | Biotech Hunter | Biotech Hunter